why choose us

300×250 Ad Slot

Drug FDA Status

Showing 110 of 158 result(s) (Page 11 of 16)
Drug Name: Letybo

Active Ingredient: letibotulinumtoxinA-wlbg

Approval Date: 2024-02-29

Description: To temporarily improve the appearance of moderate-to-severe glabellar lines
Drug Trials Snapshot

Drug Name: Exblifep

Active Ingredient: cefepime, enmetazobactam

Approval Date: 2024-02-22

Description: To treat complicated urinary tract infections
Drug Trials Snapshot

Drug Name: Zelsuvmi

Active Ingredient: berdazimer

Approval Date: 2024-01-05

Description: To treat molluscum contagiosum
Drug Trials Snapshot

Drug Name: Wainua

Active Ingredient: eplontersen

Approval Date: 2023-12-21

Description: To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis
Drug Trials Snapshot

Drug Name: Filsuvez

Active Ingredient: birch triterpenes

Approval Date: 2023-12-18

Description: To treat wounds associated with dystrophic and junctional epidermolysis bullosa

Drug Name: Fabhalta

Active Ingredient: iptacopan

Approval Date: 2023-12-05

Description: To treat paroxysmal nocturnal hemoglobinuria

Drug Name: Ogsiveo

Active Ingredient: nirogacestat

Approval Date: 2023-11-27

Description: To treat adults with progressing desmoid tumors who require systemic treatment

Drug Name: Truqap

Active Ingredient: capivasertib

Approval Date: 2023-11-16

Description: To treat breast cancer that meets certain disease criteria

Drug Name: Ryzneuta

Active Ingredient: efbemalenograstim alfa-vuxw

Approval Date: 2023-11-16

Description: To treat neutropenia
Drug Trials Snapshot

Drug Name: Augtyro

Active Ingredient: repotrectinib

Approval Date: 2023-11-15

Description: To treat ROS1-positive non-small cell lung cancer

300×250 Ad Slot